Cognex Corporation $CGNX Shares Sold by Alpine Peaks Capital LP

Alpine Peaks Capital LP lowered its stake in shares of Cognex Corporation (NASDAQ:CGNX) by 5.6% during the fourth quarter, Holdings Channel reports. The firm owned 138,019 shares of the scientific and technical instruments company’s stock after selling 8,200 shares during the period. Cognex makes up approximately 4.7% of Alpine Peaks Capital LP’s investment portfolio, making the stock its 11th largest position. Alpine Peaks Capital LP’s holdings in Cognex were worth $4,966,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in CGNX. Geneos Wealth Management Inc. raised its holdings in Cognex by 402.2% during the first quarter. Geneos Wealth Management Inc. now owns 919 shares of the scientific and technical instruments company’s stock worth $27,000 after purchasing an additional 736 shares in the last quarter. CIBC Private Wealth Group LLC raised its holdings in Cognex by 74.8% during the third quarter. CIBC Private Wealth Group LLC now owns 764 shares of the scientific and technical instruments company’s stock worth $35,000 after purchasing an additional 327 shares in the last quarter. Miller Global Investments LLC acquired a new stake in Cognex during the fourth quarter worth approximately $39,000. Caitong International Asset Management Co. Ltd acquired a new stake in Cognex during the fourth quarter worth approximately $39,000. Finally, Larson Financial Group LLC raised its holdings in Cognex by 202.7% during the fourth quarter. Larson Financial Group LLC now owns 1,105 shares of the scientific and technical instruments company’s stock worth $40,000 after purchasing an additional 740 shares in the last quarter. Institutional investors and hedge funds own 88.12% of the company’s stock.

Cognex Price Performance

Shares of Cognex stock opened at $64.77 on Thursday. The firm’s fifty day simple moving average is $60.66 and its 200-day simple moving average is $50.02. The stock has a market capitalization of $10.78 billion, a price-to-earnings ratio of 77.11 and a beta of 1.52. Cognex Corporation has a 12 month low of $29.22 and a 12 month high of $71.90.

Cognex (NASDAQ:CGNX) last announced its quarterly earnings data on Wednesday, May 6th. The scientific and technical instruments company reported $0.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.25 by $0.09. The company had revenue of $268.44 million for the quarter, compared to analysts’ expectations of $245.98 million. Cognex had a net margin of 13.62% and a return on equity of 10.89%. Cognex’s revenue was up 24.3% compared to the same quarter last year. During the same period in the previous year, the company posted $0.14 EPS. Cognex has set its Q2 2026 guidance at 0.400-0.440 EPS. Analysts anticipate that Cognex Corporation will post 1.41 earnings per share for the current year.

Cognex Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, June 4th. Shareholders of record on Thursday, May 21st were paid a $0.085 dividend. This represents a $0.34 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend was Thursday, May 21st. Cognex’s payout ratio is currently 40.48%.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on CGNX shares. The Goldman Sachs Group reissued a “buy” rating and set a $80.00 price objective (up from $70.00) on shares of Cognex in a report on Monday, May 11th. Barclays reissued an “overweight” rating and set a $75.00 price objective (up from $64.00) on shares of Cognex in a report on Monday, May 11th. Zacks Research cut shares of Cognex from a “strong-buy” rating to a “hold” rating in a report on Tuesday, April 14th. JPMorgan Chase & Co. raised shares of Cognex from a “neutral” rating to an “overweight” rating and lifted their target price for the company from $65.00 to $75.00 in a report on Tuesday, May 26th. Finally, Stephens lifted their target price on shares of Cognex from $65.00 to $75.00 and gave the company an “overweight” rating in a report on Thursday, May 7th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $70.43.

Insider Buying and Selling at Cognex

In other Cognex news, insider Mark Fennell sold 64,873 shares of the business’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $67.05, for a total value of $4,349,734.65. Following the transaction, the insider directly owned 11,263 shares of the company’s stock, valued at approximately $755,184.15. The trade was a 85.21% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Darren Marc Long sold 20,252 shares of the business’s stock in a transaction on Wednesday, May 27th. The shares were sold at an average price of $66.34, for a total transaction of $1,343,517.68. Following the completion of the transaction, the vice president directly owned 3,990 shares in the company, valued at $264,696.60. This represents a 83.54% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 224,847 shares of company stock valued at $14,975,098. 1.70% of the stock is owned by company insiders.

About Cognex

Cognex Corporation is a leading provider of machine vision systems, software, sensors and industrial barcode readers used to automate manufacturing, logistics and distribution processes. The company designs and develops vision-based products that help manufacturers and logistics operators inspect, identify and guide parts, assemblies and packaged goods in real time. Its solutions are applied in a broad range of industries, including automotive, electronics, semiconductor, pharmaceutical, food and beverage, and general manufacturing.

The company’s product portfolio includes stand-alone vision systems, vision sensors and deep learning-based software platforms that enable automated inspection, quality control and traceability.